IOVANCE BIOTHERAPEUTICS, INC.: financial reference

Limits of the selected measures

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic: This weighted-average share observation is withheld because the original statement labels share counts in thousands, while its inline tag encodes the displayed count with scale zero and unit shares. The conflicting source presentation is retained; no multiplication, replacement value or tag correction has been applied.

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic: This older Iovance weighted-average share observation is withheld because its scale-zero share tag conflicts with the original statement’s in-thousands heading. The conflict is preserved without multiplying, relabeling or replacing the source value.

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding: This weighted-average share observation is withheld because the original statement labels share counts in thousands, while its inline tag encodes the displayed count with scale zero and unit shares. The conflicting source presentation is retained; no multiplication, replacement value or tag correction has been applied.

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding: This older Iovance weighted-average share observation is withheld because its scale-zero share tag conflicts with the original statement’s in-thousands heading. The conflict is preserved without multiplying, relabeling or replacing the source value.

Context from the filing

For Iovance in 2023–2025, the filing excludes outstanding potential common shares as anti-dilutive in its net-loss-per-share calculation. It identifies options, ESPP purchases, restricted stock units and preferred-stock conversion as potential dilution. This review covers only the reported USD EPS observations. Separate weighted-average share observations remain withheld for their source scale conflict; EPS is not recomputed from those withheld counts. Read the source filing.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Inspect the source

Entity

IOVANCE BIOTHERAPEUTICS, INC. / CIK 0001425205

Captured

2026-09-20T08:03:45.999Z

SEC response SHA-256

bb58496635d85ba57e1fe3f80d062d09fbf1db1b6d80eb6e8ba8eda9321f7680

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001425205.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))